B+
Bull case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
IMMX
Immix BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The cleanest bull argument is that enrollment completion has turned IMMX from a vague pipeline story into a dated Q3 2026 readout setup, while the year-end cash balance and expected CIRM support reduce immediate financing pressure into that catalyst window [#8-K-2026-03-30] [#10-K-2026-03-25].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.7.
What can break
CIRM grant support is milestone-based and subject to compliance and disbursement conditions, so reimbursement timing is not fully in management control [#10-K-2026-03-25].
Momentum
97
Value
41
Sentiment
35
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $15.00 · Bear $4.50Analysis 2026-04-29; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $22.29
Why
Momentum97 · Δ7d -0.5
Value41 · Δ7d -0.0
Sentiment35 · Δ7d +6.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.7.
Contradictions & invalidation
- • CIRM grant support is milestone-based and subject to compliance and disbursement conditions, so reimbursement timing is not fully in management control [#10-K-2026-03-25].
- • Low coverage and limited external validation raise the risk that sentiment and price action remain volatile around sparse company updates.
- • The bear case is that this remains a low-coverage, single-key-catalyst biotech with binary data risk, no recent trusted-news support in the packet, and explicit 10-K language that additional capital will be needed beyond the current 12-month runway view [#10-K-2026-03-25].
Catalyst clock
2026-05-15
Q1 burn and runway disclosure should test cash-duration assumptions
Lead driver: Sentiment · See AI snapshot
Momentum
97
9% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
+7.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
35
62% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
+4.3
Why this grade
Composite grade D. Momentum 97.0 / Value 41.2 / Sentiment 35.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-29. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$811.26M
Beta
0.31
Shares Out
71.54M
P/E (TTM) · Derived
-12.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.32
Rev YoY
-
EPS YoY
-18.0%
Gross Margin
-
Op Margin
-
Net Debt
-$99.34M
Current Ratio
25.13
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data